Drugs giant GlaxoSmithKline has joined forces with US non-profit organisation
PATH (Program for Appropriate Technology in Health) to develop its malaria
vaccine. GSK鈥檚 vaccine was 70 per cent effective in protecting people against
malaria in preliminary trials鈥攖he best result for any malaria vaccine so
far. PATH will pay GSK $6.7 million to develop it further for use in
young children, who are at highest risk of dying from malaria. GSK hopes to have
a vaccine by 2008, which it plans to distribute in Africa and other endemic
areas 鈥渁t a very reasonable price鈥�.
More from New 女生小视频
Explore the latest news, articles and features
Health
Personalised cancer vaccine expected to be approved next year
News
Technology
Brazil presidential election dogged by alleged bias by Meta AI tools
News
Health
Body temperature may drive the higher risk of autoimmune conditions in women
News
Comment
Emily St. John Mandel: ‘I don’t want to write something relentlessly bleak’
Culture
Popular articles
Trending New 女生小视频 articles